Skip to main content

Congress Can Boost Prescription Drug Affordability by Increasing Transparency for Middlemen

November 16, 2026

The Honorable Chuck Grassley
Chair
U.S. Senate Committee on the Judiciary
Washington, DC 20510

The Honorable Dick Durbin
Ranking Member
U.S. Senate Committee on the Judiciary
Washington, DC 20510

Dear Chair Grassley, Ranking Member Durbin, and Members of the Committee,

On behalf of National Taxpayers Union, the nation’s oldest taxpayer advocacy organization, we commend the Committee for holding a hearing entitled “Prescribing Sunshine: How Competition & Transparency Lowers Prescription Drug Costs.” Ensuring prescription drugs remain affordable and widely accessible is essential to controlling the growth of U.S. health care spending and limiting the burden federal health programs impose on taxpayers. We encourage the Committee to explore how promoting transparency in the prescription drug supply chain can reduce costs without limiting access for patients.

The Committee is right to focus its attention on prescription drug affordability. Unfortunately, federal policy in recent years has singled out drug manufacturers with price controls while leaving other actors such as pharmacy benefit managers (PBMs), insurers, and hospitals out of comprehensive policy solutions. Studies show that intermediaries in the pharmaceutical supply chain capture about one-third of total drug expenditures. Any serious effort to control spending on drugs therefore needs to address the incentives and distortions across the prescription drug supply chain, instead of just squeezing pharmaceutical manufacturers with self-defeating price controls.

Lawmakers should focus their attention on the role that middlemen such as PBMs play in making prescription drugs more expensive than they need to be. By aggregating purchasing power and negotiating rebates, PBMs can play an important role in helping control drug spending for employers and government programs. However, growing consolidation in recent years, along with opaque pricing practices, raise legitimate concerns that savings are not always passed down to patients and taxpayers.

NTU encourages the Committee to focus its efforts on increasing transparency, especially around the practice of spread pricing, where PBMs keep the difference between what they charge health plans and what they reimburse pharmacies. These hidden markups inflate federal health spending, and taxpayers stand to benefit tremendously from reforms that bring greater accountability and clarity to how federal health dollars are spent. Furthermore, additional disclosure from PBMs on the use of specialty pharmacies in Medicare and Medicaid would help address current gaps in CMS reporting requirements.

We appreciate the Committee’s leadership on this issue and stand ready to assist in developing legislative solutions that put patients first.

Sincerely,

Alexander Ciccone
Policy and Government Affairs Manager
National Taxpayers Union